← All Royalty Pharma PLC filings

Royalty Pharma PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RPRX
Royalty Pharma PLC
10-K: Royalty Pharma's 2025 Performance: Strong Growth, Strategic Internalization
Royalty Pharma reports robust 16.2% growth in Portfolio Receipts to $3.3 billion in 2025, driven by strategic acquisitions and product performance, despite a dip in net income attributable to shareholders.
NASDAQ
RPRX
Royalty Pharma PLC
10-K: Royalty Pharma Reports $2.8 Billion in Portfolio Receipts, Plans Manager Internalization
Royalty Pharma's 10-K filing reveals strong portfolio performance and a strategic move to acquire its manager, signaling a shift towards internal management.
NASDAQ
RPRX
Royalty Pharma PLC
10-K: Royalty Pharma Details Share Structure and Voting Rights in SEC Filing
Royalty Pharma's recent SEC filing outlines the company's share capital structure, including Class A and Class B ordinary shares, and their respective voting and dividend rights.